Evaluation Tackling Myths about Long-Acting Injectables in Schizophrenia: LAIs are a Last Resort for Patients (Module 2) Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Desire Matthews, PMHNP-BC 5 4 3 2 1 Veronica Ridpath, DO 5 4 3 2 1 Max Guttman, LCSW 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Assess patient-related barriers and clinician-held misconceptions that limit optimal schizophrenia treatment, and outline strategies to address/overcome them 5 4 3 2 1 Outline best practices and guideline recommendations derived from clinical trial and real-world data for the therapeutic use of LAIs to optimize outcomes 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Schizophrenia on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage Schizophrenia. Excellent Very Good Good Fair Poor In 2021, the American Psychiatric Association supported which of the following statements regarding the use of long-acting injectable (LAI) antipsychotic treatments? LAIs should be recommended based on preference or a history of uncertain adherence Oral anti-psychotics must be used in all patients before LAIs to identify efficacy Patient goals and tobacco use should be considered when recommending LAIs Psychosocial intervention requirements are mitigated by use of LAIs Based on my participation in this activity, I anticipate I will more often: (select all that apply) Offer LAIs to a greater number of my adult patients with schizophrenia Offer an LAI to patients who are currently stable on an oral antipsychotic Offer an LAI to a new patient after an initial psychotic episode Discuss techniques to mitigate needle pain when describing LAIs to my patients Remain apprised of new and emerging clinical data regarding LAIs in schizophrenia Discuss a range of LAIs with different amenities of care (such as lower injection volumes and different administration method) to patients Administer LAIs in practice; Refer patients who prefer LAIs for an injection Address barriers to the clinical integration and administration of LAIs (eg, storage, preparation, and administration limitations) Revisit discussion of LAIs at subsequent visits after a patient initially refuses LAIs Inform patients who previously refused or discontinued LAIs that newer LAI options are available with more amenities of care Describe the clinical benefits of LAIs (such as reduced risk of relapse and convenience of administration regimen) before mentioning the injection route of the administration Use motivational interviewing to deconstruct patient resistance to LAIs Wait for the patient to initiate conversations about LAI therapy Follow guideline recommendations derived from clinical trial and real-world data for the therapeutic use of LAIs Address patient-related barriers and misconceptions that limit the introduction of LAIs in schizophrenia treatment Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Previous
